Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: Provided are processes for the use of a single dried blood sample for the preparation of test samples including targets of differing structures. The processes allow the same dried blood sample to be used for preparation of a first test sample including a non-nucleic acid target, and the same dried blood sample to be subsequently processed for preparation of a test sample that includes a nucleic acid target whereby the processes preserve the ability of the nucleic acid to be detected in subsequent detection assays following prior isolation of non-nucleic acid targets.

Abstract: The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.

Abstract: Disclosed herein are methods for identifying the effects, including off target effect, of genomic modification of primary cells. These methods are performed with high accuracy suitable for validating therapeutic T-cell engineering approaches.

Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.

Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.

Abstract: The present invention relates to methods for diagnosing, monitoring, and optionally treating eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE), the methods comprising assaying one or more tissue, serum, or plasma biomarkers in a biological sample from the subject.

Abstract: The present disclosure relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.

Abstract: The present invention is directed to a method for detecting the presence or absence of an antiviral drug-resistant HSV, comprising: (a) identifying one or more HSV mutation selected from: (i) a thymidine kinase (TK) mutation selected from 250G>A (HSV-2), 0C>T (HSV-1), 268C>T (HSV-2), 373C>T (HSV-1), 146T>G (HSV-1), 363G>A (HSV-), 497T>A (HSV-1), 558G>T (HSV-2), 641A>G (HSV-2), 715T>C (HSV-1), 938T>C(HSV-2), 437_438insA (HSV-1), 169delC (HSV-1), 170delC (HSV-1), 171delC (HSV-1), 1072delC (HSV-1), 458delC (HSV-2), 459delC (HSV-2), 460delC (HSV-2), 461delC (HSV-2), 881delC (HSV-1), 882delC (HSV-1), 883delC (HSV-1), 884delC (HSV-1), and 885delC (HSV-1); and (ii) a DNA polymerase (DNA pol) mutation selected from 1882C>G(HSV-2), 2405T>G (HSV-1), 2500G>T (HSV-1), 2515A>G (HSV-1), 2892_2893insT(HSV-1), 2893_2894insT (HSV-1), 2894_2895insT (HSV-1), and 2895_2896insT (HSV-1); wherein the presence of said one or more HSV mutation confirms the presence of an antiviral drug-res

Abstract: Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNF SF15 (or TL1A) and/or DcR3 genetic loci.

Abstract: A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.

Abstract: The present invention relates to methods for diagnosing, monitoring, and optionally treating eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE), the methods comprising assaying one or more tissue, serum, or plasma biomarkers in a biological sample from the subject.

Abstract: The present invention relates to a novel method for stabilizing nucleic acid nanostructures by curing with ultraviolet light, particularly by crosslinking pyrimidine nucleotides.

Abstract: A method for introducing a foreign gene into a cell according to an embodiment of the present disclosure can easily identify foreign gene introduction by detecting whether there is fluorescent emission or not, and can reduce influence of additional elements other than a target gene since any reporter gene or selectable marker is not required. Further, the inventive method does not need an additional sampling process and therefore may implement a relatively accurate and simple screening process.

Abstract: The present invention relates to an epigenetic method for identifying IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked) syndrome and/or IPEX-like syndrome in a human subject using the methylation status of F0XP3 and a control gene specific for a CD4 and/or CD3 T cell. The method is used to distinguish IPEX from IPEX-like and from IPEX-unrelated disorders.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: The present invention relates to a method of analyzing and detecting RNA. In particular, the present invention is capable of analyzing RNA with short base sequences while quantitatively detecting RNA with high sensitivity and accuracy, and thus can be widely used for diagnosis of various diseases such as infectious diseases and cancer.